Clinical Trial Update: [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is assessing [68Ga]Ga DOTA-5G as a diagnostic imaging agent for metastatic invasive lobular breast cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Lobular Breast Cancer

Drugs mentioned

• [68Ga]Ga DOTA-5G (gallium-68 labeled DOTA-5G)

Snippet

Sponsor: University of California, Davis | Conditions: Metastatic Lobular Breast Carcinoma | Phase 1 | Status: RECRUITING